FBI NGI June 2019 Fact Sheet Statistics:

• The FBI Next Generation Identification (NGI) database 
contains the fingerprints of over 142.6 million individuals 
(both civil and criminal). 
•  Over 98% of the Tenprint Rapsheet Request (TPRS) 
responses were completed within 20 seconds. 

Fiscal Year 2019 Average

In Touch with Your World

FREEDOM TO TRAVEL ABROAD

For the Pharma Technology Industry

FBI fingerprint-based background checks are increasingly required for U.S. Citizens to live, work and travel overseas in many countries such as China, South Korea, Australia, South Africa, Spain and Israel.

Accurate Biometrics was the first authorized FBI Channeler, to provide access to FBI Identity History Summary Checks (IdHS), or Departmental Orders (556-73). For 20 years we have been a leader in the fingerprint industry with our technology capabilities, expertise and dedicated service to government agencies and private industries.

Our expertise will assist your company:

  • Obtain access to Identity History Summary Checks
    for Visa requirements direct from the FBI CJIS
  • National U.S. Collection Network, over 700 locations in 50 states
  • SAME DAY International fingerprint card processing
  • NEW! Accurate Biometrics is the first FBI Channeler approved to 
    provide Cloud Channeling Technology
  • Customized solution-based service to public and private 
    companies to meet their fingerprinting needs

For more information, contact...

Will Peterson 
Director of Business Development
708-887-9258
wpeterson@accuratebiometrics.com
AccurateBiometrics.com

Go to article: Home | Saving face: PR in pharma Go to article: In this issueGo to article: Emirates SkyCargoGo to article: ContentsGo to article: Hapa Company Insight Go to article: Owen MumfordGo to article: NewsGo to article: Dupont PharmaceuticalsGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: The pharma industry briefingGo to article: Scandinavian Health Ltd.Go to article: Gerteis Company InsightGo to article: GerteisGo to article: Coughs and sneezes spread diseases: charting the development of flu vaccinesGo to article: Swiss WorldCargoGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: ‘Don’t put baby in the corner’: overcoming challenges in paediatric drug developmentGo to article: Qatar AirwaysGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: Debate: should countries bring critical drug production home?Go to article: AirBridgeCargo Company InsightGo to article: AirBridgeCargoGo to article: Capsugel Company Insight Go to article: Beyond Viagra Town: profiling the Irish pharma industryGo to article: Daiichi JitsugyoGo to article: TSS Company Insight Go to article: TSSGo to article: Recurrent miscarriage: could this devastating condition have a simple cure?Go to article: LB Bohle Company Insight Go to article: LB BohleGo to article: Public image limited: the role of PR in pharmaGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: Q&A: Gavi alliance talks immunising 300 million people Go to article: Spirax Sarco Company Insight Go to article: Spirax SarcoGo to article: Bias remorse: are cancer drug trials clear enough on outcomes?Go to article: Zenatek Go to article: B&W TekGo to article: Deals in brief powered by GlobalDataGo to article: Centaur Clinical Insight Go to article: Centaur ClinicalGo to article: The key list powered by GlobalDataGo to article: AlpexGo to article: PfanstiehlGo to article: EventsGo to article: MimotopesGo to article: NymiGo to article: Next issue